NTRN (Neutron) fluctuates 57.4% in 24 hours: Official announcement of entry into long-term maintenance mode triggers sell-off panic
Bitget Pulse2026/03/18 15:12Volatility Summary
NTRN experienced significant price fluctuations in the past 24 hours, reaching a high of $0.0085 and a low of $0.0054. The current price is $0.006, with an amplitude of 57.4%. The 24-hour trading volume surged to approximately $4.03 million, up 81.4% from the previous day. Spot trading volume is around $1.94 million, futures trading volume about $5.61 million, and there are clear signs of net capital outflow.
Brief Analysis of Abnormal Movement Causes
- The Neutron official team announced on the evening of March 16 that the project would shift to “long term support” mode, ending four years of active development and prioritizing the return of value to stakeholders. This news directly triggered panic selling in the market.
- Following the announcement, trading volume surged, with Bitget reporting volatility of 42.9%. Selling pressure dominated, causing the price to quickly fall from its peak.
Market Opinion and Outlook
Community sentiment is predominantly fearful. Users on X are concerned that the value of NTRN tokens may go to zero or the “project may end,” with many questioning whether it's a “scam.” Technical analysis shows NTRN is in a clear downtrend, with RSI nearing oversold levels but overall outlook remains bearish. Further selling pressure should be watched for, and it is recommended to wait for a clear reversal signal.
Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.